These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29853278)

  • 1. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():80-84. PubMed ID: 29853278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():75-79. PubMed ID: 29843897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for effective treatment of vitamin K antagonist-associated bleeding.
    Yates SG; Sarode R
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S180-6. PubMed ID: 26149021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
    Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
    Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER; Murillo JR; Putney D; Hobaugh EC
    J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Vicente V; Romiti GF; Romanazzi I; Proietti M; Valdés M; Marín F; Lip GYH
    Int J Cardiol; 2018 Mar; 254():125-131. PubMed ID: 29248163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
    Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
    BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
    Sarode R
    Clin Lab Med; 2014 Sep; 34(3):613-21. PubMed ID: 25168946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis.
    Skaistis J; Tagami T
    PLoS One; 2015; 10(9):e0137444. PubMed ID: 26383245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
    Weitz JI; Pollack CV
    Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of bleeding with oral anticoagulants in patients with atrial fibrillation.
    Bosch J; Eikelboom JW
    Hamostaseologie; 2015; 35(4):351-7. PubMed ID: 26013362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.